News
- Author:
- Ted Bosworth
Publish date: March 15, 2024
At interim analysis, a stem cell extension study shows favorable clinical and biomarker effects for progressive MS.
News
- Author:
- Ted Bosworth
Publish date: March 14, 2024
FROM AAD 2024
SAN DIEGO — In separate studies evaluating treatme...
News
- Author:
- Ted Bosworth
Publish date: March 12, 2024
Patient-reported outcomes in multiple sclerosis (MS) matter, but remain underused due to multiple barriers.
News
- Author:
- Ted Bosworth
Publish date: March 12, 2024
ASCLEPIOS substudies find high sNfL levels at 3 and 12 months predictive of future CNS activity in patients with MS.
News
- Author:
- Ted Bosworth
Publish date: March 12, 2024
“Once we understand the biology, we can turn barriers into opportunities.”
News
- Author:
- Ted Bosworth
Publish date: March 11, 2024
Many of the changes in the 2024 NCCN guidelines capture incremental advances rather than a radical departure from previous practice.
News
- Author:
- Ted Bosworth
Publish date: March 4, 2024
Paramagnetic rim lesions (PRLs) predict cognitive impairment among other signs of aggressive multiple sclerosis.
News
- Author:
- Ted Bosworth
Publish date: December 4, 2023
After some negative studies with PFO closure, attention is returning to this strategy for migraine prevention.
News
- Author:
- Ted Bosworth
Publish date: November 28, 2023
The distinct molecular events in each phase of migraine suggest the prevention and treatment targets differ.
News
- Author:
- Ted Bosworth
Publish date: November 28, 2023
Clinical training might explain the delay in diagnosis of nail psoriasis in patients with darker skin types.
News
- Author:
- Ted Bosworth
Publish date: November 27, 2023
Complete responses continued to increase in open-label extensions of phase 3 alopecia areata studies.
News
- Author:
- Ted Bosworth
Publish date: November 27, 2023
Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
News
- Author:
- Ted Bosworth
Publish date: November 27, 2023
Two biologics that inhibit both IL-17A and 17F effectively controlled hidradenitis suppurativa in phase 3 trials.
News
- Author:
- Ted Bosworth
Publish date: November 22, 2023
Combined with imaging, artificial intelligence (AI) identifies risk in setting of nonobstructive coronary disease.
News
- Author:
- Ted Bosworth
Publish date: November 21, 2023
For the parent, the pigmentation changes, rather than the inflammation, might be the governing issue and the reason that he or she brought the chil...
